Takeda Pharmaceutical Company Ltd
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Safety and Efficacy Study of Ramelteon in Subjects With Chronic Insomnia
Phase 3
Completed
- Conditions
- Sleep Initiation and Maintenance Disorders
- Interventions
- Drug: PlaceboDrug: Ramelteon
- First Posted Date
- 2008-09-19
- Last Posted Date
- 2010-06-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 259
- Registration Number
- NCT00756002
Efficacy of Pioglitazone and Fortamet Combination Therapy in Subjects With Type 2 Diabetes
Phase 4
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2010-07-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 312
- Registration Number
- NCT00754403
Efficacy and Safety of Peginesatide Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Participants Previously Treated With Epoetin.
- First Posted Date
- 2008-09-15
- Last Posted Date
- 2012-08-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 59
- Registration Number
- NCT00752791
Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.
- First Posted Date
- 2008-09-15
- Last Posted Date
- 2012-07-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 102
- Registration Number
- NCT00752609
Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.
- First Posted Date
- 2008-09-01
- Last Posted Date
- 2014-03-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 301
- Registration Number
- NCT00744627
Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
- First Posted Date
- 2008-08-15
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 560
- Registration Number
- NCT00735709
An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
- First Posted Date
- 2008-08-13
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 304
- Registration Number
- NCT00734071
Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 457
- Registration Number
- NCT00731120
Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
Phase 3
Completed
- Conditions
- Generalized Anxiety Disorder
- Interventions
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 781
- Registration Number
- NCT00730691
Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.
Phase 3
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2008-08-04
- Last Posted Date
- 2011-07-29
- Lead Sponsor
- Takeda
- Target Recruit Count
- 600
- Registration Number
- NCT00727857
© Copyright 2025. All Rights Reserved by MedPath